Form D · Pharmaceuticals
Sentonix, Inc.
Arlington, MA · CIK 0002039609
Offering snapshot reported Aug 20, 2026 · SEC filing
- Reported sold
- $12.7M Offering amount: $21.2M
- Investors reported
- 17 Form D · investor count
- Minimum accepted
- $250K Reported outside-investor minimum
- First sale
- Aug 13, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 20, 2026 | Initial | $12,704,719 | No comparison | 17 | SEC filing |
| May 12, 2025 | Amendment | $6,499,590 | $1,294,000vs Oct 3, 2024 | 15 | SEC filing |
| Oct 3, 2024 | Initial | $5,205,590 | No comparison | 10 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-594851
Total Offering Amount and Total Amount Sold includes conversion of $11,203,719.19 in convertible promissory notes for which a Form D was previously filed on October 3, 2024.
Source: Form D, filed Aug 20, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| John Beaver | Director, Executive |
| Jack Hoppin | Director |
| Karl Schmidt | Executive |
| Kenan Turnacioglu | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
1167 Massachusetts Ave
Arlington, MA, 02476
Phone: 617-388-6440
Arlington, MA, 02476
Phone: 617-388-6440